FDA Approves clinical application of ignyta immunomodulator rxdx-106 for solid tumor treatment

Source: Sina Pharmaceutical News on December 29, 2018-01-02, ignyta, a tumor precision medical biotechnology company, which has been purchased by Roche with us $1.7 billion, said publicly that the US FDA approved the company's candidate drug rxdx-106 for clinical trial application (ind) of solid tumor treatment, which is a TAM (TYRO3, Axl, MER) inhibitor and a new oral immunomodulator drug After the approval of this ind application, ignyta company will start the research of targeted immunomodulatory Tam antibody (rxdx-106) in patients with locally advanced or metastatic solid tumors This is a multi center open label dose increasing test, which is the first one in the population Titan test will mainly evaluate the safety, tolerance, pharmacodynamics and preliminary effectiveness of rxdx-106 Dr Jonathan Lim, chairman and CEO of ignyta, said: "rxdx-106 is a representative of new tumor immunotherapy drugs, and we are very excited to obtain the approval of clinical trials Through previous preclinical studies, rxdx-106 has demonstrated that targeting Tam receptor family in tumor microenvironment, whether single drug therapy or combination with immunosuppressant, can stimulate and enhance the potential of immune response to cancer This candidate drug further enhances our commitment to developing new drugs for cancer patients The clinical phase 1 trial will begin in early 2018 " Rxdx-106 is a new oral immunomodulator with strong non clinical antitumor activity By inhibiting TYRO3, Axl and mer receptor tyrosine kinase (collectively referred to as TAM) and reversing the immunosuppression of innate immune cells in tumor microenvironment (TME), it can restore and enhance the immune function of the whole body In tumor microenvironment, receptor tyrosine kinase Tam promotes anti-inflammatory and tumorigenic activity, which promotes tumor cells to escape from the immune system and tumor progression As a powerful selective Tam inhibitor, rxdx-106 has the potential to reverse Tam mediated immunosuppression and inhibit tumor growth and progression Ignyta company, located in San Diego, California, USA, is a precision medical company that provides integrated Rx / DX (precise targeted treatment / diagnosis) solutions for cancer and immune disease treatment Its goal is to discover and develop revolutionary new drugs that target the activated genes in cancer cells or reactivate the immune system for personalized treatment of cancer patients On December 23, 2017, Roche announced to reach an acquisition agreement with ignyta company for us $1.7 billion, and obtained the entrectinib, a new anticancer drug under development by the latter.